Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
Creighton University
ClinicalTrials.gov Identifier:
NCT00385463
First received: October 6, 2006
Last updated: March 20, 2008
Last verified: March 2008
  Purpose

The four respiratory drugs being researched in this study have been approved by the US Food and Drug Administration (FDA) and are currently available by prescription at your drug store. One of the drugs is for the treatment of asthma alone, one is for treatment of SAR alone, and one is for treatment of both SAR and asthma. In addition, you will also receive one asthma rescue drug (albuterol) that is to be used for any breakthrough asthma symptoms that you may experience throughout the study.

The purpose of this study is to see how well your asthma and SAR are controlled when taking one of the medicine combinations


Condition Intervention
Asthma
Seasonal Allergic Rhinitis
Drug: Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray Versus Montelukast in Adolescents/Adults With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus(R) or Placebo

Resource links provided by NLM:


Further study details as provided by Creighton University:

Primary Outcome Measures:
  • Mean change from baseline at endpoint in morning PEF compared between fluticasone propionate/salmeterol combination product 100/50mcg BID (FSC) and montelukast 10mg QD (MON) treatment groups.
  • Assess superiority and compare between FSC and FSC+MON treatment groups
  • Assess equivalence.

Secondary Outcome Measures:
  • Rhinitis mean change from baseline in subject-rated: daily, total nasal symptom scores averaged over Weeks 1-2 and nighttime total nasal symptom scores averaged over Weeks 1-2.
  • Asthma assess superiority and assess equivalence: mean change from baseline at endpoint in predose AM FEV1; percentage of asthma rescue-free days; and percentage of asthma rescue-free days

Estimated Enrollment: 600
Study Start Date: April 2006
Study Completion Date: April 2007
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Detailed Description:

4-week study to assess asthma control as measured by lung function and clinical features, rhinitis treatment, subject-rated overall satisfaction with treatment, and safety outcomes when FLONASE™ 200mcg (FPANS) QD, Singulair 10mg (MON) QD, or placebo QD is added to ADVAIR™ DISKUS™ 100/50mcg (FSC) BID and when Singulair 10mg (MON) QD is added to placebo DISKUS BID in adolescent and adults subjects. Male or female subjects must be symptomatic with both seasonal allergic rhinitis and persistent asthma, and have an FEV1 65-95% of predicted while using an as-needed short-acting beta2-agonist or an allowed ICS or non-ICS controller therapy. Subjects will replace their short-acting beta2-agonist with VENTOLIN™ HFA (for rescue) and will enter a 7-14 day run-in period during which they will continue use of their pre-study controller therapy. At Visit 2, subjects who meet both the asthma and rhinitis randomization criteria will be randomized to double-blind treatment with ADVAIR DISKUS 100/50mcg BID and either FLONASE 200mcg QD, Singulair 10mg QD, or placebo QD, or to placebo DISKUS BID and Singulair 10mg QD. The co-primary efficacy measures will be the mean change from baseline at endpoint in AM PEF, compared between the FSC and the MON treatment groups to assess superiority and compared between the FSC and FSC+MON treatment groups to assess equivalence. Secondary efficacy measures for rhinitis will be mean change from baseline in subject-rated daytime total nasal symptom score and nighttime total nasal symptomatic score averaged over Weeks 1-2 (D-TNSSW1-2 and N-TNSSW1-2, respectively). Secondary efficacy measures for asthma will be mean change from baseline at endpoint in morning pre-dose FEV1, percentage of symptom-free days, and percentage of rescue-free days. Other measures will include subject-rated overall satisfaction with treatment, evening PEF, asthma symptom scores (D-INSSW1-x, N-INSSW1-2), averaged over Weeks 1-2. Descriptive measures will include all total and individual nasal symptoms scores averaged over Weeks1-4. Safety measures will include assessment of clinical adverse events and asthma exacerbations.

  Eligibility

Ages Eligible for Study:   15 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Signed and dated written informed consent is obtained.
  • Male or female
  • 15 Years and older
  • Diagnosis of persistent asthma for at least three months.
  • 3 months prior and current use of specified asthma therapies
  • FEV1 between 65-95% of predicted value
  • Diagnosis of seasonal allergic rhinitis
  • Active residence within geographical regions where exposure to relevant seasonal allergic is expected

Exclusion Criteria:

  • Currently diagnosed with life-threatening asthma
  • Asthma instability
  • Concurrent respiratory disease
  • Nasal obstruction
  • Nasal history
  • Certain concurrent conditions/diseases
  • Drug allergy
  • Respiratory tract infections
  • Specific (listed in protocol) concurrent medications
  • Systemic corticosteroids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00385463

Locations
United States, Nebraska
Creighton University
Omaha, Nebraska, United States, 68131
Sponsors and Collaborators
Creighton University
GlaxoSmithKline
Investigators
Principal Investigator: Robert Townley, M.D. Creighton University
  More Information

No publications provided

Responsible Party: Robert G. Townley, MD, Creighton University
ClinicalTrials.gov Identifier: NCT00385463     History of Changes
Other Study ID Numbers: GSK ADA103575
Study First Received: October 6, 2006
Last Updated: March 20, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Creighton University:
Asthma
Rhinitis
Allergic Asthma

Additional relevant MeSH terms:
Asthma
Rhinitis
Rhinitis, Allergic, Perennial
Rhinitis, Allergic, Seasonal
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Nose Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Respiratory Tract Diseases
Respiratory Tract Infections
Albuterol
Fluticasone, salmeterol drug combination
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on November 23, 2014